Basic Information
| LncRNA/CircRNA Name | MEG3 |
| Synonyms | NA |
| Region | GRCh38_14:100779410-100861031 |
| Ensemble | ENSG00000214548 |
| Refseq | NR_002766 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | malignant melanoma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot |
| Sample | malignant melanoma tissues, cell lines (A375, SK-MEL-1, B16, A2058, and HEMa-LP) |
| Expression Pattern | down-regulated |
| Function Description | MEG3 was obviously decreased in melanoma cells compared to human epidermal melanocytes HEMa-LP. MEG3 was restored by transfecting LV-MEG3 in to A375 and A2058 cells. Subsequently, we found that overexpression of MEG3 was able to inhibit cell proliferation and colony formation capacity. Meanwhile, melanoma cell apoptosis was induced by up-regulation of MEG3. Overexpression of MEG3 greatly repressed melanoma cell migration and invasion ability. In addition, Wnt signaling pathway has been identified in the progression of various cancers. Here, in our study, it was indicated that Wnt signaling was highly activated in melanoma cells with ?-catenin expression significantly increased and GSK-3? decreased. Interestingly, MEG restoration strongly inactivated Wnt signaling pathway by reducing ?-catenin and CyclinD1, elevating GSK-3? levels in vitro. Finally, in vivo experiments were carried out to confirm the inhibitory roles of MEG3 in vivo. |
| Pubmed ID | 29781534 |
| Year | 2018 |
| Title | LncRNA MEG3 Repressed Malignant Melanoma Progression via Inactivating Wnt Signaling Pathway |
External Links
| Links for MEG3 | GenBank HGNC NONCODE |
| Links for malignant melanoma | OMIM COSMIC |